XSOLLA
8.8.2024 18:01:37 CEST | Business Wire | Press release
Xsolla, a global video game commerce company, announces the opening of its first Canadian office in Montreal in collaboration with GameAddik. This strategic expansion into one of North America's most dynamic tech hubs underscores Xsolla's dedication to innovation and its mission to better serve the burgeoning gaming industry and developers in Quebec and across Canada.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240808870268/en/
(Graphic: Xsolla)
Montreal has long been recognized for its dynamic gaming ecosystem and innovative tech community. By establishing a presence in this thriving city, Xsolla aims to expand its operations with incredible local talent and foster closer relationships with regional developers. The new office will serve as a hub for Xsolla's operations in Canada, enhancing its ability to offer tailored and localized solutions to its current partners and thousands of new game developers and publishers in the region.
"Montreal is renowned for its dynamic gaming ecosystem and innovative tech community. Our presence here will enable us to better support our local and global partners and tap into the incredible local talent pool," said Xsolla's president, David Stelzer. “This new office in Montreal will be crucial in strengthening our relationships with local game developers and facilitating our mission to empower our partners to reach their full potential.”
As part of this expansion, Xsolla plans to hire up to 50 regional employees over the next two years, targeting a mix of roles in business development, customer support, and technical services. This investment will strengthen its capacity to deliver cutting-edge solutions and exceptional service.
This strategic partnership with GameAddik originated from the successful cross-service opportunities explored with its dedicated marketing solution, GameRebellion, creating a robust support system for game developers in Canada.
"We are excited about our collaboration with Xsolla, as our GameRebellion project shares a common vision of empowering studios to achieve greater success," said Alain Carpentier, CTO at GameAddik.
"Our partnership with Xsolla is a game-changer for GameAddik," said Eric Jodoin, CEO of GameAddik. "Teaming up with such a prominent company allows us to better support the industry in striving for success."
The new office will be a one-stop shop for companies looking for industry-leading and cutting-edge solutions to fund, launch, market, monetize, and sell their games to local gamers and fans of their games worldwide. Xsolla provides advanced tools and services to help game developers accelerate their business by reaching players who want to pay for their gaming experiences locally using their preferred payment methods. With the ability to enable transactions in over 130 currencies and 20 languages, Xsolla has already facilitated access to new gamers for game developers worldwide.
For more information about the Xsolla Canadian office, please visit xsolla.pro/montreal.
About Xsolla
Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch, and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in Montreal, London, Berlin, Beijing, Guangzhou, Seoul, Tokyo, Kuala Lumpur, Raleigh, and cities around the world, Xsolla supports major gaming titles like Valve, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, and more.
For additional information and to learn more, please visit xsolla.com.
About GameAddik
Founded in 2015, GameAddik is an advertising technology company that provides tech-driven marketing solutions for the gaming industry. Trusted by over 200 global brands, GameAddik is a leader in understanding gaming audiences and delivering measurable performance marketing solutions for its clients across its three business segments: PWN Games (performance marketing), Elusive (performance-driven influencer marketing), and GameRebellion (game audience and industry data and analytics).
For more information, please visit gameaddik.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240808870268/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
vVARDIS Announces Investment from Apollo—Achieves Unicorn Status27.4.2026 14:51:00 CEST | Press release
Investment will support global commercial expansion of the Curodont™ technology platform, the first and only non-invasive peptide-containing formulations designed to treat tooth decay drill-free throughout the depth of the lesion vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. vVARDIS is redefining the treatment of cavities through its Curodont™ technology, the first and only commercially available non-invasive peptide-containing formulati
IAS Launches IAS Total TV Solutions Giving Marketers ‘Linear-like’ Transparency for Connected TV27.4.2026 14:30:00 CEST | Press release
‘IAS Total TV’ unlocks show, genre and rating transparency measurement across Disney, NBCUniversal, Paramount and Prime Video, plus multiple opted-in publishers using Publica enabling advertisers to enhance brand suitability while increasing campaign outcomes Integral Ad Science (IAS) today announced ‘IAS Total TV’, a new comprehensive suite of Connected TV (CTV) solutions designed specifically to bring ‘linear-like’ transparency to streaming TV. IAS Total TV can provide marketers with genre, rating, language, show and program-level data in aggregate from Disney, NBCUniversal, Paramount and Prime Video, in addition to multiple opted-in publishers using Publica. IAS Total TV integrates content insights, media quality, supply path and outcomes into a unified view within the IAS Signal user interface (UI). Advertisers can determine when and how they want their advertising to run alongside CTV content, ensuring brand-related and brand suitable environments. “As advertisers continue to doub
Riskified Study Finds Consumers Aren’t Ready to Hand Over Control as AI Transforms Shopping, with Over Half Afraid of Online Fraud27.4.2026 14:00:00 CEST | Press release
New Q1 2026 “Agentic Commerce Pulse” survey from Riskified reveals a growing trust gap in agent-driven commerce, as consumers embrace AI across the shopping journey but remain hesitant to hand over control amid concerns over fraud, security, and accountability Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today released the Q1 2026 edition of its Agentic Commerce Pulse, a quarterly research series tracking agentic commerce risks and consumer engagement. Following Riskified’s inaugural Q4 2025 survey, which first highlighted the rapid emergence of agent-driven commerce, the latest findings reveal a more complex reality: while AI adoption remains strong, consumer trust is not keeping pace. A widening gap is emerging between how shoppers use AI and how much control they are willing to give it. The survey, conducted among consumers across the United States and the United Kingdom, shows that AI is now firmly embedded in product discovery and decision-maki
Nine in 10 Expect Cross-Border M&A Surge, But 71% of Dealmakers Have Already Changed Course on Deals27.4.2026 14:00:00 CEST | Press release
90% of dealmakers expect cross-border M&A activity to increase over the next 12–24 months75% cite foreign direct investment screening as the biggest threat to deal completion88% report longer signing-to-close timelines than three years ago Cross-border M&A is set for a strong resurgence, with nine in 10 senior dealmakers expecting activity to increase over the next 12 to 24 months, according to new research from CSC, the leading provider of business administration and compliance solutions. However, despite this renewed momentum, execution risk is rising, with regulatory scrutiny and operational challenges making it harder to get deals over the line. CSC¹ surveyed 200 director level and above global dealmakers across private equity, corporate, legal, and advisory roles who have worked on cross-border transactions in the past two years. The report, The New Reality of Cross-Border M&A: More Deals, More Friction, explores how firms are navigating an increasingly complex global deal environ
Mundipharma announces positive topline results from Phase III ReSPECT trial assessing ▼REZZAYO® (rezafungin) for the prophylaxis of invasive fungal diseases in allogeneic haematopoietic stem cell transplantation patients27.4.2026 13:43:00 CEST | Press release
For Trade and Medical Media Only The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal-free survival at Day 90 Study showed favourable benefit for toxicity-related discontinuations and drug-drug interactions (DDIs) Rezafungin was well tolerated, with a safety profile comparable to standard antimicrobial regimens (SARs) Mundipharma today announced positive Phase III topline results from the global ReSPECT clinical trial evaluating REZZAYO® (rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT). The ReSPECT Phase III trial, one of the largest antifungal, multicentre, randomised, double-blind studies evaluated the efficacy and safety of once weekly rezafungin compared with a SAR for the prophylaxis of IFDs, including infections caused by Candida, Aspergillus, and Pneumocystis, in adults undergoing allogeneic HSCT. Patients undergoing a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom